T2DM, CV Safety, and Efficacy:

DPP-4 Inhibitors in focus

DPP-4 Inhibitor CV Outcomes

Trials in T2DM

T2DM CV Outcomes Trials From

the DPP-4 Inhibitor Class

SAVOR-TIMI 53: Primary

Endpoint

SAVOR-TIMI 53:
Hospitalization for HF

EXAMINE: Primary Endpoint

EXAMINE: Hospitalization for HF

TECOS: Study Design

TECOS: Effect of Sitagliptin vs

Placebo on CV Outcomes in
T2DM

TECOS: Hospitalization for HF

DPP-4 Inhibitors: Hypoglycemia

DPP-4 Inhibitors: Pancreatitis

Future DPP-4 CV Outcomes

Trials in T2DM

Managing T2DM: incorporating

injectable fixed-dose combinations

Fixed-dose Combinations

Why Combine Basal Insulin and

GLP-1 RAs?

DUAL-I: HbA1c Comparison

DUAL-I: Percentage of Patients to

Target HbA1c

DUAL-I: Change in Body Weight

DUAL-I: Confirmed Hypoglycemia

DUAL-I: Nausea Over 26 Weeks

Addition of Insulin to GLP-1 RA

and Addition of GLP-1 RA to
Insulin in T2DM

When and How Should We Use

Combination Therapies?

T2DM, CV SAFETy, and efficacy: GLP1 Receptor Agonists

in focus

ELIXA: Severe Symptomatic

Hypoglycemia

T2DM, CV SAFETy, and efficacy:

SGLT2 Inhibitors in focus

EMPA-REG OUTCOME

EMPA-REG OUTCOME: Study Design

EMPA-REG OUTCOME: Effect of

Empagliflozin vs Placebo on the
Primary Composite Outcome

EMPA-REG OUTCOME: Effect of

Empagliflozin vs Placebo on CV
Death

EMPA-REG OUTCOME: Effect of

Empagliflozin vs Placebo on
Individual CV Endpoints

EMPA-REG OUTCOME: Effect of

Empagliflozin vs Placebo on Allcause Mortality

EMPA-REG OUTCOME: Effect of

Empagliflozin vs Placebo on HF
Hospitalization

Future SGLT2 Inhibitor CV Outcomes

Trials